{"entity":{"id":"nct06782334","kind":"trial","name":"AMT-116 in Patients with Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of AMT-116 in advanced solid tumours, run by Multitude Therapeutics Inc., now recruiting.","summary":"AMT-116 in Patients with Solid Tumors is a phase 1/2 interventional study registered as NCT06782334 by Multitude Therapeutics Inc., with 144 participants planned, started 2024-05-07 and due to reach its primary completion in 2026-06-30. Interventions recorded: AMT-116.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06782334","url":"https://clinicaltrials.gov/study/NCT06782334"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["amt-116"],"companies":["multitude-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06782334","phase":"1/2","setting":"Phase 1/2 Study of AMT-116 in Patients with Advanced Solid Tumors","sponsor":"Multitude Therapeutics Inc.","enrolled":144,"outcomes":[]},"route":"/trials/nct06782334/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"amt-116","kind":"drug","name":"AMT-116","route":"/drugs/amt-116/"}],"company":[{"id":"multitude-therapeutics","kind":"company","name":"Multitude Therapeutics","route":"/companies/multitude-therapeutics/"}]}}